Aktis Oncology, Inc.
About Aktis Oncology, Inc.
Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. The company has one operating and reportable segment focused on the research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. The company generates revenue from Collaboration agreement.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2026
- $3.2M
- Net income
- -$18.3M
- Total assets
- $576.8M
- Market cap
- $1.0B
- Gross margin
- -2.5%
- Operating margin
- -401.7%
- Net margin
- -613.3%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $27.4M
- Cost of revenue
- $28.1M
- Gross profit
- -$689.0K
- Operating expenses
- $109.3M
- Operating income
- -$110.0M
- Income tax
- $6.0K
- Net income
- -$167.9M
- EPS (basic)
- $-1.89
- EPS (diluted)
- $-1.89
Balance sheet
- Total assets
- $69.7M
- Current assets
- $36.8M
- Total liabilities
- $126.8M
- Current liabilities
- $84.4M
- Shareholders’ equity
- -$57.1M
Cash flow
- Operating cash flow
- -$40.3M
- Investing cash flow
- -$6.0M
- Financing cash flow
- $27.7M
- Net cash flow
- -$18.7M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.0B
- EPS (diluted)
- $-1.89
- Shares outstanding
- 55.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jan 9, 2026
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $18.3M in FY2026.
- Revenue grew 1430% from FY2020 to FY2024.
- Gross margin of -2.5%, net margin -613.3%.
- Trading 15% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Aktis Oncology, Inc..
Write a review
News about Aktis Oncology, Inc.
News & sentiment via Polygon.io
